{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Part+A%2C+Double-blind%29&page=5", "query": { "intervention": "Placebo (Part A, Double-blind)", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 888, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Part+A%2C+Double-blind%29&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Part+A%2C+Double-blind%29&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T11:11:04.629Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05769582", "title": "Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "BK Viremia; BKV DNAemia" ], "interventions": [ { "name": "Anti-BK polyomavirus (AntiBKV)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memo Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2023-04-10", "completion_date": "2025-07-15", "has_results": false, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-10-12T11:11:04.629Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05769582" }, { "nct_id": "NCT04285853", "title": "Are Opioids Needed After ACL Reconstruction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anterior Cruciate Ligament Rupture" ], "interventions": [ { "name": "Oxycodone", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "14 Years to 40 Years" }, "enrollment_count": 98, "start_date": "2020-09-16", "completion_date": "2022-09-19", "has_results": true, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-10-12T11:11:04.629Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Tucker, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Tucker", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04285853" }, { "nct_id": "NCT07187531", "title": "SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "High Dose SAB-142", "type": "DRUG" }, { "name": "Low Dose SAB-142", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SAb Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "5 Years to 40 Years" }, "enrollment_count": 159, "start_date": "2025-11-25", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-12T11:11:04.629Z", "location_count": 23, "location_summary": "San Francisco, California • San Jose, California • Aurora, Colorado + 20 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07187531" }, { "nct_id": "NCT05001945", "title": "Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertension, Renal" ], "interventions": [ { "name": "MLS-101 (Part I)", "type": "DRUG" }, { "name": "Placebo (Part I)", "type": "OTHER" }, { "name": "Placebo (Part II)", "type": "OTHER" }, { "name": "MLS-101 (Part II)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mineralys Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2021-07-01", "completion_date": "2022-10-07", "has_results": true, "last_update_posted_date": "2024-01-05", "last_synced_at": "2026-10-12T11:11:04.629Z", "location_count": 44, "location_summary": "Lincoln, California • Torrance, California • Tustin, California + 38 more", "locations": [ { "city": "Lincoln", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05001945" }, { "nct_id": "NCT03222973", "title": "Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "BIIB033 (opicinumab)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "58 Years", "sex": "ALL", "summary": "18 Years to 58 Years" }, "enrollment_count": 263, "start_date": "2017-11-15", "completion_date": "2021-02-12", "has_results": true, "last_update_posted_date": "2022-04-28", "last_synced_at": "2026-10-12T11:11:04.629Z", "location_count": 51, "location_summary": "Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03222973" }, { "nct_id": "NCT04644029", "title": "Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-I", "Human Immunodeficiency Virus Type 1", "Prophylaxis" ], "interventions": [ { "name": "Islatravir", "type": "DRUG" }, { "name": "Placebo to FTC/TDF", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Placebo to ISL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "16 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "16 Years to 45 Years · Female only" }, "enrollment_count": 730, "start_date": "2021-02-24", "completion_date": "2024-06-11", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-10-12T11:11:04.629Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644029" }, { "nct_id": "NCT01037725", "title": "Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "AZD5847", "type": "DRUG" }, { "name": "Placebo to AZD5847", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 64, "start_date": "2009-12", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2010-07-14", "last_synced_at": "2026-10-12T11:11:04.629Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01037725" }, { "nct_id": "NCT02018536", "title": "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "GSK2336805 30 mg", "type": "DRUG" }, { "name": "GSK2336805 60 mg", "type": "DRUG" }, { "name": "GSK2336805 120 mg", "type": "DRUG" }, { "name": "TMC435 150 mg (Treatment A)", "type": "DRUG" }, { "name": "GSK2336805 60 mg (Treatment B and part of Treatment C and D)", "type": "DRUG" }, { "name": "TMC435 100 mg (part of Treatment C)", "type": "DRUG" }, { "name": "TMC435 150 mg (part of treatment D)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "20 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2013-10", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2014-06-17", "last_synced_at": "2026-10-12T11:11:04.629Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02018536" }, { "nct_id": "NCT01315236", "title": "Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mycobacterium Infections, Nontuberculous" ], "interventions": [ { "name": "Liposomal amikacin for inhalation (LAI)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Insmed Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 90, "start_date": "2012-04-19", "completion_date": "2015-06-18", "has_results": true, "last_update_posted_date": "2019-08-21", "last_synced_at": "2026-10-12T11:11:04.629Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Stanford, California • Denver, Colorado + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01315236" }, { "nct_id": "NCT05406115", "title": "Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "AMG 786", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 65, "start_date": "2022-07-26", "completion_date": "2023-08-21", "has_results": false, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-12T11:11:04.629Z", "location_count": 3, "location_summary": "Tustin, California • Aventura, Florida • Miami, Florida", "locations": [ { "city": "Tustin", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05406115" } ] }